SCHEMBL30180863

SCHEMBL30180863

CC(C)(C)OC(=O)NC(=N)c1ccc2cc(C(=O)OC3CCC(NC(=O)OC(C)(C)C)CC3)n(Cc3cccc4ccccc34)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.36
▸ F10 P00742 5/20 0.34
▸ CACNB4 O00305 1/20 0.34
▸ CACNA1A O00555 1/20 0.34
▸ CACNA1G O43497 1/20 0.34
▸ CACNG3 O60359 1/20 0.34
▸ CACNA1F O60840 1/20 0.34
▸ CACNA1H O95180 1/20 0.34
▸ CACNB3 P54284 1/20 0.34
▸ CACNA2D1 P54289 1/20 0.34
▸ CACNG7 P62955 1/20 0.34
▸ CACNA1B Q00975 1/20 0.34
▸ CACNA1D Q01668 1/20 0.34
▸ CACNB1 Q02641 1/20 0.34
▸ CACNG1 Q06432 1/20 0.34
▸ CACNB2 Q08289 1/20 0.34
▸ CACNA1S Q13698 1/20 0.34
▸ CACNA1C Q13936 1/20 0.34
▸ CACNA1E Q15878 1/20 0.34
▸ CACNA2D4 Q7Z3S7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25017972 0.88 F10 (0.35) EPHX1F10CACNB4CACNA1ACACNA1G
SCHEMBL25016107 0.87 F10 (0.41) EPHX1F10NQO2
SCHEMBL21822134 0.86 DRD2 (0.42) EPHX1CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL25016295 0.85 USP30 (0.41) DPP4MCL1
SCHEMBL25016100 0.85 USP30 (0.41) DPP4MCL1
SCHEMBL25017636 0.84 F10 (0.37) F10DPP4
SCHEMBL31689662 0.83 CTSS (0.42) F10CTSSCTSKMCL1NQO2
SCHEMBL21822737 0.83 CTSS (0.42) F10CTSSCTSKMCL1NQO2
SCHEMBL31689683 0.83 F10 (0.38) F10MAPK8KMT2AL3MBTL1KDM1A
SCHEMBL25017640 0.83 F10 (0.38) F10MAPK8KMT2AL3MBTL1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860636-B1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE INC (US) 2026-01-28 — — EP disclosed
US-12428415-B2 Matriptase 2 inhibitors and uses thereof DISC MEDICINE, INC. (US) 2025-09-30 — — US disclosed
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. 2023-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428415-B2 Matriptase 2 inhibitors and uses thereof MMP7, MATR3, SPINT2 EPHX1 3242/4885F10 1548/4885CACNB4 4456/4885
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF MMP7, MATR3, SPINT2 EPHX1 3242/4885F10 1548/4885CACNB4 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback